Stoke Therapeutics awards director 39,674 options

The award's first quarterly vesting date is December 23, 2026, subject to continued service through that date.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. director Alexander Cumbo received a direct award of options covering 39,674 common shares on September 23, 2026, at an exercise price of $26.11 per share; the options expire September 22, 2036. The award vests in 1/12th installments quarterly, beginning December 23, 2026, subject to continued service through each vesting date. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Grant/Award: 39,674 shares

Grant/Award 1 txn

Insider Cumbo Alexander

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	39,674	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 39,674 contracts (Direct)

Footnotes (1)

1. F1. The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

Key Figures

Option award: 39,674 options covering common shares Exercise price: $26.11 per share Option expiration: September 22, 2036 +2 more

5 metrics

Option award 39,674 options covering common shares Direct award on September 23, 2026

Exercise price $26.11 per share Options covering Stoke Therapeutics common stock

Option expiration September 22, 2036 Award to Alexander Cumbo

Quarterly vesting installment 1/12th of the total award Vests on the 23rd calendar day of each December, March, June, and September

First vesting date December 23, 2026 Subject to continued service through the vesting date

Key Terms

Director Stock Option (Right to Buy), vest, exercise price

3 terms

Director Stock Option (Right to Buy) technical

"Director Stock Option (Right to Buy)"

vest technical

"The option award shall vest as to 1/12th of the total award quarterly"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"at an exercise price of $26.11 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did STOK director Alexander Cumbo receive?

Alexander Cumbo received a direct award of options covering 39,674 shares of Stoke Therapeutics common stock on September 23, 2026. The options have an exercise price of $26.11 per share and expire on September 22, 2036.

What is the vesting schedule for Alexander Cumbo's STOK options?

The award vests as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September. The first tranche vests on December 23, 2026, subject to Alexander Cumbo's continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 04:21 PM Accepted by SEC EDGAR 09/25/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cumbo Alexander

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$26.11	09/23/2026		A		39,674		(1)	09/22/2036	Common Stock	39,674	$0	39,674	D

Explanation of Responses:

1. The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)